Objective: To assess the quality of specimens obtained from prostate biopsies performed by urology residents and evaluate the number of procedures required to perform high-quality transrectal ultrasound (TRUS)-guided prostate biopsies.
Materials And Methods: Between 2006 and 2009, 770 patients underwent TRUS-guided prostate biopsies in our academic center. During the 6 semesters of this period, 24 residents (4 per semester) performed 1 session of 5.6±1.5 procedures each month for a total of 33.6±9 procedures during the study. The first session was performed with a senior urologist. Prostate cancer detection rate and standards of quality (average length of prostatic core biopsy specimens and absence of prostatic tissue) were retrospectively studied between the beginning and the end of each semester.
Results: A total of 12,760 biopsy cores were performed for 770 procedures. Mean patient age (64.5±6.1 years), and median prostate-specific antigen (8.7±3.7 ng/mL) were comparable between the study periods. The average length of biopsy cores significantly improved (+10%) from the first (12±2.7 mm) to the last month (13.2±2.1 mm) with a plateau after 12 procedures. Overall, cancer detection rate was 47% and was stable during the semester (41.3% the first month vs 44.1% the last month; P=.39). On univariate and multivariate analysis the mean length of biopsy specimens was associated with the number of procedures (P<.001) and the number of cores performed (P<.001).
Conclusion: Twelve procedures are necessary to perform high-quality TRUS-guided prostate biopsies without compromising prostate cancer detection. In current training programs, we strongly recommend that residents have direct supervision for a minimum of 12 cases before they are allowed to perform TRUS-guided biopsies with indirect supervision.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2012.06.084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Feasibility of 3-D Acoustic Radiation Force Impulse (ARFI) Imaging for Targeted Prostate Biopsy Guidance.
Ultrason Imaging
January 2025
Department of Biomedical Engineering, Duke University, Durham, NC, USA.
We have developed a 3-D acoustic radiation force impulse (ARFI) prostate imaging system to identify regions suspicious for cancer and guide a targeted prostate biopsy in a single visit. The system uses a side-fire transrectal probe and an automated rotation stage to acquire ARFI and B-mode image volumes, combined with 3-D visualization and targeting software to enable biopsy target identification and guide a transperineal (TP) biopsy. The system was tested in the first clinical trial of its kind, with subjects serially undergoing ARFI-guided targeted TP biopsy, multiparametric magnetic resonance imaging (mpMRI)-ultrasound fusion TP biopsy, and systematic sampling TP biopsy.
View Article and Find Full Text PDFDiffuse, Bilateral Prostate Imaging Reporting and Data System (PI-RADS) 3 Changes Reported as Inflammation and Their Relation to Clinically Significant Prostate Cancer: A Retrospective Observational Study.
Cureus
December 2024
Urology, Northwick Park Hospital - London North West University Healthcare NHS Trust, Harrow, GBR.
Aim/Objective The aim of this study was to investigate if diffuse, bilateral PI-RADS (Prostate Imaging Reporting and Data System) 3 changes, reported on MRI Prostate, harbour clinically significant prostate cancer (csPCa) within them. Methods Data from 108 men with diffuse, bilateral PI-RADS 3 changes on MRI of the prostate who underwent systematic prostate biopsy between January 2000 and November 2023 were analyzed. Histology results were classified as benign or malignant, and clinically significant prostate cancer (csPCa) was defined according to the European Association of Urology (EAU) guidelines as ISUP GG (International Society for Urological Pathology Grade Group) 2 or higher.
View Article and Find Full Text PDFIntroduction Balanitis xerotica obliterans (BXO) can cause phimosis, meatal stenosis, and urethral strictures. However, management of these conditions in BXO patients is difficult. Surgical interventions, with their own risks and complications, demonstrate higher rates of disease recurrence.
View Article and Find Full Text PDFUltra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Background: Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.
View Article and Find Full Text PDFConstruction of a clinically significant prostate cancer risk prediction model based on traditional diagnostic methods.
Front Oncol
December 2024
Urology 2nd Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Objectives: to construct a prediction model for clinically significant prostate cancer (csPCa) based on prostate-specific antigen (PSA) levels, digital rectal examination (DRE), and transrectal ultrasonography (TRUS).
Methods: We retrospectively analysed 1196 Asian patients who underwent transrectal ultrasound-guided biopsy (TRUSB) between June 2000 and February 2023. Patients were randomly divided into a training set of 837 cases (70%) and a validation set of 359 patients (30%).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!